The Cooper Companies Announces Release Date For Second Quarter 2013

PLEASANTON, Calif., May 6, 2013 (GLOBE NEWSWIRE) -- The Cooper Companies, Inc. (NYSE:COO) today announced that it will release second quarter 2013 financial results on Thursday, June 6, 2013 at 4:00 PM ET. Following the release, the company will host a conference call and live webcast with investors and analysts at 5:00 PM ET to discuss the results and current corporate developments. 

The dial in number in the United States is +1-800-591-6942.  The dial in number outside the United States is +1-617-614-4909. The passcode is 17608162.

A replay will be available approximately two hours after the call ends until Thursday, June 13, 2013.  The dial in number for the replay in the United States is +1-888-286-8010. The dial in number for the replay outside the United States is +1-617-801-6888. The replay passcode is 77555127.

This call will also be broadcast live at http://investor.coopercos.com and a transcript will be available following the conference call.

About The Cooper Companies

The Cooper Companies, Inc. ("Cooper") is a global medical device company publicly traded on the NYSE Euronext (NYSE:COO). Cooper is dedicated to being A Quality of Life Company™ with a focus on delivering shareholder value. Cooper operates through two business units, CooperVision and CooperSurgical. CooperVision brings a refreshing perspective on vision care with a commitment to crafting a wide range of high-quality products for contact lens wearers and providing focused practitioner support. CooperSurgical focuses on supplying women's health clinicians with market leading products and treatment options to improve the delivery of healthcare to women. Headquartered in Pleasanton, CA, Cooper has approximately 7,800 employees with products sold in over 100 countries. For more information, please visit www.coopercos.com .

COO-G
CONTACT: Kim Duncan         Senior Director, Investor Relations         ir@cooperco.com         925-460-3663

The Cooper Companies, Inc. Logo

If you liked this article you might like

Teva Nailed With S&P Downgrade

Teva Nailed With S&P Downgrade

7 Investment Themes You Can't Afford to Miss for 2018

7 Investment Themes You Can't Afford to Miss for 2018

Teva Still Has Big Problems It Must Deal With in 2018

Teva Still Has Big Problems It Must Deal With in 2018

Teva Closes Higher as Generic Drugmaker Announces Massive Layoffs, Asset Sales

Teva Closes Higher as Generic Drugmaker Announces Massive Layoffs, Asset Sales

The 60-Year-Old Gold Bug and the 25-Year-Old Bitcoin Fan Are Alike: Market Recon

The 60-Year-Old Gold Bug and the 25-Year-Old Bitcoin Fan Are Alike: Market Recon